Quentin Deraedt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Quentin Deraedt has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Elias
Université catholique de Louvain (UCLouvain) Institut de la Matière Condensée et des Nanosciences (IMCN) Molecular Chemistry Materials and Catalysis (MOST) Place Louis Pasteur 1, bte L4.01.02 Louvain‐la‐Neuve 1348 Belgium
3 shared publications - Lionel Marcélis
Laboratory of Paediatric Research and Newborn Screening, Université Libre de Bruxelles, B-1020 Brussels, Belgium
3 shared publications Dominique Descamps
2 shared publicationsGarry S. Hanan
Département de Chimie, Université de Montréal, Montreal, Canada
2 shared publications- Veronica Hulstrøm
GSK, Wavre, Belgium
2 shared publications Agatha Cathrine Wilhase
REIMED Pty. , Boksburg
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Vaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
- 16 November 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Open AccessVaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
- Open Access
- 1 August 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (12) , 1579-1594
AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance
- 1 August 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (12) , 1579-1594
Open AccessAS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance
- Open Access
- 27 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1093-e1103
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
The AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) is approved for ≥60-year-olds and 50–59-year-olds at increased risk of RSV disease. We evaluated the vaccine's immunogenicity and safety in 18–49-year-olds at increased risk of RSV disease due to certain chronic conditions. This open-label, multicountry phase 3b trial included 18–49-year-olds at increased risk (at-risk 18–49 group) and a control group of ≥60-year-olds with or without chronic conditions (≥60 group). Primary objective was to demonstrate immunological noninferiority to adjuvanted RSVPreF3 in the at-risk 18–49 versus ≥60 group, based on group RSV-A/RSV-B geometric mean titer ratios and seroresponse rate differences 1 month postvaccination. Humoral, cell-mediated immunogenicity, and safety were assessed until 6 months postvaccination. Overall, 1458 adults were vaccinated. Immunological noninferiority was demonstrated in the at-risk 18–49 versus ≥60 group at 1 month postvaccination. Both groups showed increased RSV-A/RSV-B neutralizing titers and RSVPreF3-specific CD4+ T-cell frequencies at 1 month postvaccination that declined but remained above baseline at 6 months. Solicited events were more frequent in the at-risk 18–49 (84.3%) than in the ≥60 group (69.4%); most were mild-to-moderate and transient. Rates and intensity of unsolicited adverse events (AEs) were comparable across groups, with low reporting of serious AEs and AEs of special interest. Adjuvanted RSVPreF3 was immunologically noninferior in 18–49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487
- 27 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1093-e1103
Open AccessImmunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
The AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) is approved for ≥60-year-olds and 50–59-year-olds at increased risk of RSV disease. We evaluated the vaccine's immunogenicity and safety in 18–49-year-olds at increased risk of RSV disease due to certain chronic conditions. This open-label, multicountry phase 3b trial included 18–49-year-olds at increased risk (at-risk 18–49 group) and a control group of ≥60-year-olds with or without chronic conditions (≥60 group). Primary objective was to demonstrate immunological noninferiority to adjuvanted RSVPreF3 in the at-risk 18–49 versus ≥60 group, based on group RSV-A/RSV-B geometric mean titer ratios and seroresponse rate differences 1 month postvaccination. Humoral, cell-mediated immunogenicity, and safety were assessed until 6 months postvaccination. Overall, 1458 adults were vaccinated. Immunological noninferiority was demonstrated in the at-risk 18–49 versus ≥60 group at 1 month postvaccination. Both groups showed increased RSV-A/RSV-B neutralizing titers and RSVPreF3-specific CD4+ T-cell frequencies at 1 month postvaccination that declined but remained above baseline at 6 months. Solicited events were more frequent in the at-risk 18–49 (84.3%) than in the ≥60 group (69.4%); most were mild-to-moderate and transient. Rates and intensity of unsolicited adverse events (AEs) were comparable across groups, with low reporting of serious AEs and AEs of special interest. Adjuvanted RSVPreF3 was immunologically noninferior in 18–49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487
- Open Access
- 2 January 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2159731
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
Patients with obstructive airway diseases (OAD), like chronic obstructive pulmonary disease (COPD) and asthma, may be at increased risk of pertussis infection. Pertussis may also trigger COPD and asthma exacerbations. Vaccination against pertussis could help protect OAD patients from the additional burden of pertussis, but there may be hesitancy related to vaccine safety and immunogenicity in such patients. We performed a meta-analysis on 5 clinical trials in adults receiving reduced-antigen tetanus-diphtheria-acellular pertussis vaccine (Tdap, Boostrix, GSK), from which we selected participants on active OAD treatment. We compared immunogenicity and reactogenicity outcomes of the meta-analysis with data from the overall populations of Tdap-vaccinated adults from 6 Tdap trials (including the 5 in the meta-analysis). The meta-analysis comprised 222 adults on active standard OAD treatment. One month post-Tdap, 89.0% and 97.2% of these adults, respectively, achieved seroprotective anti-diphtheria and anti-tetanus antibody concentrations; 78.3%–96.1% showed booster responses across the 3 pertussis antigens. These rates were consistent with those in the comparator population. The most frequently reported solicited local and systemic adverse events within 4 days post-Tdap were injection site pain (47.7%) and fatigue (19.3%), with low rates of grade 3 intensity (0.9% and 2.8%). This was consistent with Tdap reactogenicity in the comparator population. Evaluation of unsolicited and serious adverse events within 1 month post-Tdap did not identify safety concerns. In conclusion, Tdap was immunogenic and well tolerated in adults under active standard OAD treatment, with immunogenicity and safety profiles consistent with those in a comparator population representing the general adult population. Whooping cough is a very contagious respiratory disease that is most dangerous for young babies but can affect people of all ages. People with chronic lung diseases like asthma or chronic obstructive pulmonary disease (COPD) may be more likely to get ill and suffer from complications from whooping cough. Vaccination against whooping cough is an important way to help protect these people. However, some doctors may hesitate to vaccinate patients because they may worry that vaccination could worsen asthma or COPD symptoms or that drugs taken by these patients could make vaccines work less well. We therefore looked at the immunogenicity and safety of a whooping cough vaccine (Boostrix, GSK) in adults treated for chronic lung diseases like asthma or COPD. We analyzed data from 5 previous clinical studies and specifically selected data from patients taking standard medication for chronic lung diseases in these studies. We found that the immune response to whooping cough vaccination in these patients was comparable to that in a comparator group representative of the general adult population receiving Boostrix. The vaccine was as well tolerated in patients with chronic lung diseases as in the general adult population. Our results suggest that the whooping cough vaccine Boostrix can be safely given to adults taking standard medication for chronic lung diseases to help prevent severe illness and complications from whooping cough.
- 2 January 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2159731
Open AccessImmunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
Patients with obstructive airway diseases (OAD), like chronic obstructive pulmonary disease (COPD) and asthma, may be at increased risk of pertussis infection. Pertussis may also trigger COPD and asthma exacerbations. Vaccination against pertussis could help protect OAD patients from the additional burden of pertussis, but there may be hesitancy related to vaccine safety and immunogenicity in such patients. We performed a meta-analysis on 5 clinical trials in adults receiving reduced-antigen tetanus-diphtheria-acellular pertussis vaccine (Tdap, Boostrix, GSK), from which we selected participants on active OAD treatment. We compared immunogenicity and reactogenicity outcomes of the meta-analysis with data from the overall populations of Tdap-vaccinated adults from 6 Tdap trials (including the 5 in the meta-analysis). The meta-analysis comprised 222 adults on active standard OAD treatment. One month post-Tdap, 89.0% and 97.2% of these adults, respectively, achieved seroprotective anti-diphtheria and anti-tetanus antibody concentrations; 78.3%–96.1% showed booster responses across the 3 pertussis antigens. These rates were consistent with those in the comparator population. The most frequently reported solicited local and systemic adverse events within 4 days post-Tdap were injection site pain (47.7%) and fatigue (19.3%), with low rates of grade 3 intensity (0.9% and 2.8%). This was consistent with Tdap reactogenicity in the comparator population. Evaluation of unsolicited and serious adverse events within 1 month post-Tdap did not identify safety concerns. In conclusion, Tdap was immunogenic and well tolerated in adults under active standard OAD treatment, with immunogenicity and safety profiles consistent with those in a comparator population representing the general adult population. Whooping cough is a very contagious respiratory disease that is most dangerous for young babies but can affect people of all ages. People with chronic lung diseases like asthma or chronic obstructive pulmonary disease (COPD) may be more likely to get ill and suffer from complications from whooping cough. Vaccination against whooping cough is an important way to help protect these people. However, some doctors may hesitate to vaccinate patients because they may worry that vaccination could worsen asthma or COPD symptoms or that drugs taken by these patients could make vaccines work less well. We therefore looked at the immunogenicity and safety of a whooping cough vaccine (Boostrix, GSK) in adults treated for chronic lung diseases like asthma or COPD. We analyzed data from 5 previous clinical studies and specifically selected data from patients taking standard medication for chronic lung diseases in these studies. We found that the immune response to whooping cough vaccination in these patients was comparable to that in a comparator group representative of the general adult population receiving Boostrix. The vaccine was as well tolerated in patients with chronic lung diseases as in the general adult population. Our results suggest that the whooping cough vaccine Boostrix can be safely given to adults taking standard medication for chronic lung diseases to help prevent severe illness and complications from whooping cough.
- 22 May 2019
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 6 (9) , 2260-2270
Photodetection of DNA mismatches by dissymmetric Ru(ii) acridine based complexes
The early detection of DNA mutations such as DNA mismatches is of major interest. Indeed, the accumulation of mismatches into the genome arises from deficiencies of the cellular mismatch repair machinery that is often associated with several types of cancers being resistant to classic chemotherapeutics. In this context, ruthenium(II) compounds bearing a planar extended ligand appear to be excellent candidates as DNA photoprobes since they exhibit high affinity for DNA as well as tuneable luminescence properties. Herein, we report on the synthesis of a novel dissymmetric acridine based Ru(II) complex, [Ru(bpy)2napp]2+, along with the study of its ability to photodetect DNA mismatches. We also investigated the origin of the ability of the complex to photodetect mismatches via CD-melting assays and bio-layer interferometry. Interestingly, this behaviour may be attributed to a better protection of the excited state of the complex from non-radiative deexcitation sources (e.g., collisions with the solvent, oxygen photosensitization, etc.) when intercalated into well-matched compared to mismatched DNA.
- 22 May 2019
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 6 (9) , 2260-2270
Photodetection of DNA mismatches by dissymmetric Ru(ii) acridine based complexes
The early detection of DNA mutations such as DNA mismatches is of major interest. Indeed, the accumulation of mismatches into the genome arises from deficiencies of the cellular mismatch repair machinery that is often associated with several types of cancers being resistant to classic chemotherapeutics. In this context, ruthenium(II) compounds bearing a planar extended ligand appear to be excellent candidates as DNA photoprobes since they exhibit high affinity for DNA as well as tuneable luminescence properties. Herein, we report on the synthesis of a novel dissymmetric acridine based Ru(II) complex, [Ru(bpy)2napp]2+, along with the study of its ability to photodetect DNA mismatches. We also investigated the origin of the ability of the complex to photodetect mismatches via CD-melting assays and bio-layer interferometry. Interestingly, this behaviour may be attributed to a better protection of the excited state of the complex from non-radiative deexcitation sources (e.g., collisions with the solvent, oxygen photosensitization, etc.) when intercalated into well-matched compared to mismatched DNA.
- 2 November 2016
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 4 (1) , 91-103
Towards mismatched DNA photoprobes and photoreagents: “elbow-shaped” Ru(ii) complexes
Due to their potentially harmful consequences, the detection of mismatched DNA is a subject of high interest. In order to probe DNA mismatches by means of luminescent sensitive Ru(II) complexes, “elbow-shaped” extended planar ligands based on an acridine or phenazine core have been synthesized (npp = naphtho[1,2-b]pyrido[3,2-f][1,7]phenanthroline and bdppz = benzo[h]dipyrido[3,2-a:2′,3′-c]phenazine). The photophysical studies revealed that [Ru(bpy)2npp]2+ (bpy = 2,2′-bipyridine) allows emission from a 3MLCTbpy/npp excited state, while the lowest 3MLCT for [Ru(bpy)2bdppz]2+ shifts from a bright 3MLCTbpy/pz state towards a poorly luminescent 3MLCTbdp state, probably due to the formation of H-bonds with water molecules in the excited state. Studies of the complexes in the presence of DNA demonstrate that they strongly bind to polynucleotides. In the presence of single base mismatched hairpin oligonucleotides, while [Ru(bpy)2npp]2+ does not show remarkable sensitivity to the nature of the mismatch site, [Ru(bpy)2bdppz]2+ exhibits noticeably differential luminescence behavior correlated to the nature and stability of the mismatch compared to the well-matched sequence. Photooxidant analogues of these complexes were prepared, replacing bpy ancillary ligands by bpz (2,2′-bipyrazine). A photo-induced electron transfer from dGMP and polynucleotides to the excited states of [Ru(bpz)2npp]2+ and [Ru(bpz)2bdppz]2+ is observed. These results emphasized the role of “elbow-shaped” Ru(II) complexes as promising candidates for the development of mismatch-sensitive DNA photoprobes.
- 2 November 2016
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 4 (1) , 91-103
Towards mismatched DNA photoprobes and photoreagents: “elbow-shaped” Ru(ii) complexes
Due to their potentially harmful consequences, the detection of mismatched DNA is a subject of high interest. In order to probe DNA mismatches by means of luminescent sensitive Ru(II) complexes, “elbow-shaped” extended planar ligands based on an acridine or phenazine core have been synthesized (npp = naphtho[1,2-b]pyrido[3,2-f][1,7]phenanthroline and bdppz = benzo[h]dipyrido[3,2-a:2′,3′-c]phenazine). The photophysical studies revealed that [Ru(bpy)2npp]2+ (bpy = 2,2′-bipyridine) allows emission from a 3MLCTbpy/npp excited state, while the lowest 3MLCT for [Ru(bpy)2bdppz]2+ shifts from a bright 3MLCTbpy/pz state towards a poorly luminescent 3MLCTbdp state, probably due to the formation of H-bonds with water molecules in the excited state. Studies of the complexes in the presence of DNA demonstrate that they strongly bind to polynucleotides. In the presence of single base mismatched hairpin oligonucleotides, while [Ru(bpy)2npp]2+ does not show remarkable sensitivity to the nature of the mismatch site, [Ru(bpy)2bdppz]2+ exhibits noticeably differential luminescence behavior correlated to the nature and stability of the mismatch compared to the well-matched sequence. Photooxidant analogues of these complexes were prepared, replacing bpy ancillary ligands by bpz (2,2′-bipyrazine). A photo-induced electron transfer from dGMP and polynucleotides to the excited states of [Ru(bpz)2npp]2+ and [Ru(bpz)2bdppz]2+ is observed. These results emphasized the role of “elbow-shaped” Ru(II) complexes as promising candidates for the development of mismatch-sensitive DNA photoprobes.
- 14 July 2016
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2016 (22) , 3649-3658
Design and Photophysical Studies of Acridine‐Based RuII Complexes for Applications as DNA Photoprobes
A series of new extended planar aromatic ligands based on an acridine core (dpac = dipyrido[3,2‐a:2′,3′‐c]acridine; dpacF2 = 7,8‐difluorodipyrido[3,2‐a:2′,3′‐c]acridine; dpacF4 = 6,7,8,9‐tetrafluorodipyrido[3,2‐a:2′,3′‐c]acridine) and their respective RuII complexes were synthesized and extensively studied. The photophysical and theoretical studies revealed that Ru‐DPAC and Ru‐DPACF2 allow emission from a 3MLCTphen/dpac excited state at 597 and 604 nm, respectively, whereas the lowest excited state for Ru‐DPACF4 shifts from a bright 3MLCTphen/dpac state towards a poorly luminescent 3MLCTdpac state (λem = 609 nm) owing to the formation of hydrogen bonds with water molecules in the excited state. These complexes exhibit up to sevenfold luminescence enhancement in the presence of complementary and mismatched DNA, demonstrating a strong binding to polynucleotides. The results emphasize the interest in RuII complexes bearing acridine derivatives as DNA interacting agents as a complement to the well‐known phenazine‐based derivatives.
- 14 July 2016
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2016 (22) , 3649-3658
Design and Photophysical Studies of Acridine‐Based RuII Complexes for Applications as DNA Photoprobes
A series of new extended planar aromatic ligands based on an acridine core (dpac = dipyrido[3,2‐a:2′,3′‐c]acridine; dpacF2 = 7,8‐difluorodipyrido[3,2‐a:2′,3′‐c]acridine; dpacF4 = 6,7,8,9‐tetrafluorodipyrido[3,2‐a:2′,3′‐c]acridine) and their respective RuII complexes were synthesized and extensively studied. The photophysical and theoretical studies revealed that Ru‐DPAC and Ru‐DPACF2 allow emission from a 3MLCTphen/dpac excited state at 597 and 604 nm, respectively, whereas the lowest excited state for Ru‐DPACF4 shifts from a bright 3MLCTphen/dpac state towards a poorly luminescent 3MLCTdpac state (λem = 609 nm) owing to the formation of hydrogen bonds with water molecules in the excited state. These complexes exhibit up to sevenfold luminescence enhancement in the presence of complementary and mismatched DNA, demonstrating a strong binding to polynucleotides. The results emphasize the interest in RuII complexes bearing acridine derivatives as DNA interacting agents as a complement to the well‐known phenazine‐based derivatives.